{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:14:18Z","timestamp":1787004858907,"version":"build-2736575974"},"reference-count":45,"publisher":"Georg Thieme Verlag KG","issue":"09","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Geburtshilfe Frauenheilkd"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>For the treatment of patients with advanced HER2-negative hormone receptor-positive breast cancer, several substances have been introduced into practice in recent years. In addition, other\n\t\t\t\t\tdrugs are under development. A number of studies have been published over the past year which have shown either an advantage for progression-free survival or for overall survival. This\n\t\t\t\t\treview summarizes the latest results, which have been published at current congresses or in specialist journals, and classifies them in the clinical treatment context. In particular, the\n\t\t\t\t\timportance of therapy with CDK4\/6 inhibitors \u2013 trastuzumab deruxtecan, sacituzumab govitecan and capivasertib \u2013 is discussed. For trastuzumab deruxtecan, an overall survival benefit in\n\t\t\t\t\tHER2-negative breast cancer with low HER2 expression (HER2-low expression) was reported in the Destiny-Breast-04 study. Similarly, there was an overall survival benefit in the FAKTION study\n\t\t\t\t\twith capivasertib. The lack of overall survival benefit for palbociclib in the first line of therapy raises the question of clinical classification.<\/jats:p>","DOI":"10.1055\/a-1912-7362","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T19:38:37Z","timestamp":1663097917000},"page":"922-931","source":"Crossref","is-referenced-by-count":8,"title":["Update Breast Cancer 2022 Part 4 \u2013 Advanced-Stage Breast Cancer"],"prefix":"10.1055","volume":"82","author":[{"given":"Bahriye","family":"Aktas","sequence":"additional","affiliation":[{"name":"Department of Gynecology, University of Leipzig Medical Center, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja N.","family":"Fehm","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Hospital D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Welslau","sequence":"additional","affiliation":[{"name":"Onkologie Aschaffenburg, Aschaffenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkmar","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"L\u00fcftner","sequence":"additional","affiliation":[{"name":"Immanuel Hospital M\u00e4rkische Schweiz & Medical University of Brandenburg Theodor-Fontane, Brandenburg, Buckow, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Sch\u00fctz","sequence":"additional","affiliation":[{"name":"Gyn\u00e4kologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[{"name":"Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen,\n\t\t\t\t\tGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Janni","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Thomssen","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Witzel","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Belleville","sequence":"additional","affiliation":[{"name":"ClinSol GmbH & Co KG, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Untch","sequence":"additional","affiliation":[{"name":"Clinic for Gynecology and Obstetrics, Breast Cancer Center, Gynecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Thill","sequence":"additional","affiliation":[{"name":"Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Tesch","sequence":"additional","affiliation":[{"name":"Oncology Practice at Bethanien Hospital, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Ditsch","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Lux","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe, Frauenklinik St.\u00a0Louise, Paderborn, St.\u00a0Josefs-Krankenhaus, Salzkotten, St.\u00a0Vincenz Krankenhaus GmbH, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Banys-Paluchowski","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Kolberg-Liedtke","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas D.","family":"Hartkopf","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"W\u00f6ckel","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Christian","family":"Kolberg","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"Stickeler","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, RWTH University Hospital Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[{"name":"Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human Epidermal Growth Factor Receptor 2\u2009Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"A C Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma","volume":"33","author":"N Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.3389\/fimmu.2019.02683","article-title":"CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy","volume":"10","author":"M C Burger","year":"2019","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.3390\/cancers13215577","article-title":"Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes","volume":"13","author":"R Erber","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"A L Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"A Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000516420","article-title":"AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021","volume":"16","author":"M Thill","year":"2021","journal-title":"Breast Care (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.breast.2020.08.011","article-title":"Initial experience with CDK4\/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast\n\t\t\t\t\tcancer \u2013 Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany","volume":"54","author":"A Schneeweiss","year":"2020","journal-title":"Breast"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1055\/a-1880-0087","article-title":"Implementation of CDK4\/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients \u2013 Data from the Real-World Registry PRAEGNANT","author":"T Engler","year":"2022","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","author":"S Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","article-title":"Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind,\n\t\t\t\t\tplacebo-controlled, phase 3 trial","volume":"18","author":"J Baselga","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer","volume":"380","author":"F Andre","year":"2019","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","article-title":"PI3K inhibitors are finally coming of age","volume":"20","author":"B Vanhaesebroeck","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41571-022-00633-1","article-title":"At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy","volume":"19","author":"N Vasan","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1470-2045(19)30817-4","article-title":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre,\n\t\t\t\t\trandomised, controlled, phase 2 trial","volume":"21","author":"R H Jones","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1200\/JCO.2022.40.16_suppl.1005","article-title":"Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor\u2013positive breast cancer (FAKTION):\n\t\t\t\t\tOverall survival and updated progression-free survival data with enhanced biomarker analysis","volume":"40","author":"R H Jones","year":"2022","journal-title":"J Clin Oncol"},{"issue":"S 03","key":"ref19","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.1016\/annonc\/annonc894","article-title":"Updated overall survival (OS) results from the first-line (1\u2009L) population in the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+\/HER2? advanced breast cancer (ABC)\n\t\t\t\t\ttreated with ribociclib (RIB) + fulvestrant (FUL)","volume":"33","author":"P Neven","year":"2022","journal-title":"Ann Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","volume":"386","author":"G N Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"LBA1003","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1003","article-title":"Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor\u2013positive\/human epidermal growth factor\n\t\t\t\t\treceptor 2\u2013negative advanced breast cancer (ER+\/HER2\u2212 ABC): Analyses from PALOMA-2","volume":"40","author":"R S Finn","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref22","first-page":"GS3-05","article-title":"Fulvestrant-palbociclib vs. continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a\n\t\t\t\t\tUCBG-GINECO randomized phase 3 trial","volume":"2021","author":"F Bidard","year":"2021","journal-title":"San Antonio Breast Cancer Symposium"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"D M Goldenberg","year":"2018","journal-title":"Oncotarget"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2147\/OTT.S162447","article-title":"Targeting Trop-2 in solid tumors: future prospects","volume":"12","author":"S Zaman","year":"2019","journal-title":"Onco Targets Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.17305\/bjbms.2021.6100","article-title":"Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers","volume":"22","author":"S Vranic","year":"2022","journal-title":"Bosn J Basic Med Sci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2147\/OTT.S354048","article-title":"TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer","volume":"15","author":"X Liu","year":"2022","journal-title":"Onco Targets Ther"},{"key":"ref28","first-page":"GS3-06","article-title":"Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"2020","author":"S A Hurvitz","year":"2020","journal-title":"San Antonio Breast Cancer Symposium"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"LBA1001","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1001","article-title":"Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician\u02bcs choice (TPC) in patients (Pts) with hormone\n\t\t\t\t\treceptor\u2013positive\/HER2-negative (HR+\/HER2-) advanced breast cancer","volume":"40","author":"H S Rugo","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","volume":"375","author":"G N Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer","volume":"35","author":"M P Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"R S Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer","volume":"381","author":"S A Im","year":"2019","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"PD2-04-PD02-04","DOI":"10.1158\/1538-7445.Sabcs20-pd2-04","article-title":"Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive\/human epidermal growth factor\n\t\t\t\t\treceptor 2 negative (HR+\/HER2\u2212) advanced breast cancer (ABC) treated with endocrine therapy (ET) \u00b1 ribociclib","volume":"81","author":"D Tripathy","year":"2021","journal-title":"Cancer Res"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","author":"D Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"viii90","DOI":"10.1093\/annonc\/mdy272","article-title":"Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib plus fulvestrant: Results from MONALEESA-3","volume":"29","author":"P A Fasching","year":"2018","journal-title":"Ann Oncol"},{"issue":"S 05","key":"ref42","doi-asserted-by":"publisher","first-page":"v851","DOI":"10.1093\/annonc\/mdz1394","article-title":"Overall Survival Results from the Phase 3 MONALEESA-3 Study of Fulvestrant \u00b1 Ribociclib in Postmenopausal Patients With HR+\/HER2\u2212 Advanced Breast Cancer","volume":"30","author":"D J Slamon","year":"2019","journal-title":"Ann Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer","volume":"382","author":"D J Slamon","year":"2020","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3","volume":"36","author":"D J Slamon","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized\n\t\t\t\t\tClinical Trial","volume":"6","author":"G W Sledge jr.","year":"2020","journal-title":"JAMA Oncol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+\/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","volume":"35","author":"G W Sledge jr.","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1200\/JCO.2021.39.15_suppl.1000","article-title":"Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor\u2013positive (HR+), human epidermal growth factor receptor 2\u2013negative (HER2\u2013) advanced breast\n\t\t\t\t\tcancer (ABC): Updated analyses from PALOMA-3","volume":"39","author":"M Cristofanilli","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer","volume":"373","author":"N C Turner","year":"2015","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer","volume":"379","author":"N C Turner","year":"2018","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","article-title":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","volume":"27","author":"B Xu","year":"2021","journal-title":"Nat Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2021.06.033","article-title":"Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status","volume":"155","author":"A Hein","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"P Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"321","DOI":"10.4048\/jbc.2017.20.4.321","article-title":"Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer","volume":"20","author":"Z Yi","year":"2017","journal-title":"J Breast Cancer"}],"container-title":["Geburtshilfe und Frauenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1912-7362.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T05:28:32Z","timestamp":1676006912000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1912-7362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":45,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2022,9,13]]},"published-print":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1912-7362","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0016-5751","1438-8804"],"issn-type":[{"value":"0016-5751","type":"print"},{"value":"1438-8804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}